Liguzinediol
Liguzinediol is a Bcl-2 upregulator that exerts cardioprotective effects by upregulating Bcl-2, downregulating Bax and cleaved caspase-3, and inhibiting myocardial apoptosis, RAAS, oxidative stress, inflammation, and extracellular matrix remodeling. Liguzinediol can be used for research on heart failure and cardiac fibrosis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 909708-65-2
- 화학식: C8H12N2O2
- 분자량:168.20
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
제품 설명
IC50 & Target
[1]|
Bax |
Bcl-2 |
Caspase-3 |
In Vitro
Liguzinediol (10 μM) inhibits Ang II-stimulated cardiac fibroblast proliferation, ameliorates Ang II-stimulated morphological changes in cardiac fibroblasts, and reduces the ratio of type I/III collagen in Ang II-stimulated cardiac fibroblasts[2].
Liguzinediol (10 μM) downregulates MMP-2 and MMP-9 expression and upregulates TIMP-1 expression in Ang II-stimulated cardiac fibroblasts[2].
Liguzinediol (1-100 μM) produces a positive inotropic effect in isolated rat hearts without causing chronotropic changes[5].
Liguzinediol (100 μM) has no effect on the action potential duration of rat papillary muscle and left ventricular myocytes[5].
The positive inotropic effect of Liguzinediol (100 μM) is not mediated by β-AR, PDE, Na+-K+ ATPase, α1-AR, dopamine D1 receptor, or Na+-Ca2+ exchanger in isolated rat hearts[5].
Liguzinediol (100 μM) increases Ca2+ transients in rat left ventricular cardiomyocytes and restores caffeine-induced SR Ca2+ depletion[5].
Liguzinediol (100 μM) does not increase L-type Ca2+ channel current in rat left ventricular myocytes[5].
The positive inotropic effect of Liguzinediol (100 μM) is mediated by ryanodine receptor-dependent Ca2+ release in isolated rat hearts[5].
The positive inotropic effect of liguzinediol (100 μM) is mediated through SERCA2a-dependent Ca2+ handling in isolated rat hearts[5].
Liguzinediol (100 μM; 30 min) inhibits the activities of PP1 and PP2A in rat left ventricular tissue extracts, reducing PP1 activity to 86.0% of the control level and PP2A activity to 88.8% of the control level[6].
Liguzinediol (1-100 μM; 30 min) increases phosphorylation at PLB Ser-16 and Thr-17 sites in isolated rat ventricular myocytes in a concentration-dependent manner, reaching maximum ratios of 0.85 (p-PLB Ser-16/total PLB) and 0.35 (p-PLB Thr-17/total PLB) at 100 μM, respectively[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:rat ventricular myocytes
-
Concentration:1, 10, 100 μM
-
Incubation Time:30 min
-
Result:Increased phosphorylation at PLB Ser-16 and Thr-17 sites in isolated rat ventricular myocytes in a concentration-dependent manner.
Parmacokinetics
In Vivo
Liguzinediol (5-20 mg/kg; i.g.; once daily; two weeks) exerts protective effects against DOX-induced cardiac fibrosis in rats by reducing hydroxyproline content, decreasing the ratio of collagen type I/III, downregulating MMP-2 and MMP-9, and upregulating TIMP-1[2].
Liguzinediol (5-20 mg/kg; p.o.; daily; 8 weeks) alleviates myocardial infarction-induced heart failure in rats, and its protective effect is associated with the regulation of the TGF-β1/Smads pathway[3].
Liguzinediol (1-100 μM; retrograde coronary perfusion) produces a dose-dependent positive inotropic effect in isolated rat hearts, increasing LVDP to 187 mm Hg at 100 μM without changing heart rate[5].
Liguzinediol (20 mg/kg; intravenous injection; single administration) significantly increases left ventricular contractility in healthy male Sprague Dawley rats[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (Male, 250 g, doxorubicin-induced cardiotoxicity)[1]
-
Dosage:5, 10, 20 mg/kg/d
-
Administration:p.o.; once daily; 2 weeks
-
Result:Improved left ventricular systolic pressure (LVSP) to 110.47 mmHg and +LV dp/dtmax to 5693.05 mmHg/s at 10 mg/kg.
Improved LVSP to 122.80 mmHg and +LV dp/dtmax to 6502.72 mmHg/s at 20 mg/kg.
Showed -LV dp/dtmax of 4212.46 mmHg/s at 5 mg/kg.
Showed Bcl-2 protein content of 0.71, Bax protein content of 1.07, and Bax/Bcl-2 ratio of 1.52 at 10 mg/kg.
Showed pro-caspase-3 protein content of 0.94 and cleaved-caspase-3 protein content of 1.85 at 10 mg/kg.
Attenuated DOX-induced injury of cardiomyocytes, decreased the number of apoptotic bodies, and resulted in normal appearing nuclei, mitochondria with only minimal swelling, and normal appearing lamellar cristae at 10 mg/kg/d.
Weakened NF-κB staining and limited the number of myocardial fiber fractures and decreased the extent of inflammatory cell infiltration at 10 mg/kg.
-
Animal Model:Sprague-Dawley rats (male, 250 ± 20 g, doxorubicin-induced cardiac fibrosis)[2]
-
Dosage:5, 10, 20 mg/kg
-
Administration:i.g.; once daily; two weeks
-
Result:Improved myocardial fiber fracture, myocardial vacuolar degeneration, and inflammatory cell infiltration at 5 mg/kg.
Reduced breakage of myocardial fiber and vacuolar degeneration significantly at 10 mg/kg.
Showed a small amount of vacuolar degeneration at 20 mg/kg.
Led to a reduction in blue collagen fibers at 5 mg/kg.
Showed significantly less blue collagen fibers than the model group at 10 mg/kg.
Almost completely prevented the deposition of blue collagen at 20 mg/kg.
Decreased hydroxyproline content in a dose-dependent manner.
Decreased the ratio of type I/III collagen to 5.06 at 10 mg/kg.
Lowered MMP-2 protein abundance to 1.21 at 10 mg/kg.
Lowered MMP-9 protein content to 0.81 at 10 mg/kg.
Increased TIMP-1 protein content to 0.69 at 10 mg/kg.
-
Animal Model:Sprague-Dawley (Male, 250-300 g, myocardial infarction-induced heart failure)[3]
-
Dosage:5, 10, 20 mg/kg
-
Administration:p.o.; daily; 8 weeks
-
Result:Up-regulated EF and LVFS at 5, 10, 20 mg/kg.
Improved SV at 10, 20 mg/kg.
Inhibited the increase of LVEDs at 20 mg/kg.
Up-regulated LVSP, ±dp/dtmax, SBP, DBP and MAP, and down-regulated LVEDP at 5, 10, 20 mg/kg.
Reduced HMI and LVMI at 10, 20 mg/kg.
Reduced collagen deposition and myocardial fibrosis, reversed the increase of HYP, and reduced collagen I and III contents at 5, 10, 20 mg/kg.
Reduced IL-6 and TNF-α levels at 5, 10, 20 mg/kg.
Inhibited the increase of IL-1β at 10, 20 mg/kg.
Reversed the increase of MDA and increased SOD level at 5, 10, 20 mg/kg.
Reduced serum TGF-β, reversed increases of TGF-β1, p-Smad2, p-Smad3 and CD105, and promoted Smad7 expression at 5, 10, 20 mg/kg.
-
Animal Model:Sprague-Dawley (SD) (male, 300-350 g)[5]
-
Dosage:1 μM; 10 μM; 100 μM
-
Administration:retrograde coronary perfusion
-
Result:Increased LVDP from a control value of 102 mm Hg to 134 mm Hg (1 μM), 158 mm Hg (10 μM), and 187 mm Hg (100 μM) in a dose-dependent manner.
Increased +dp/dtmax from 2502 mm Hg/s (control) to 2773 mm Hg/s (1 μM), 3130 mm Hg/s (10 μM), and 3551 mm Hg/s (100 μM).
Increased −dp/dtmax from 1773 mm Hg/s (control) to 1957 mm Hg/s (1 μM), 2203 mm Hg/s (10 μM), and 2594 mm Hg/s (100 μM).
Did not alter heart rate across all doses (167 bpm, 169 bpm, and 160 bpm vs. control 163 bpm).
Upon washout, LVDP returned to 110 mm Hg, +dp/dtmax to 2683 mm Hg/s, and −dp/dtmax to 1843 mm Hg/s.
-
Animal Model:Sprague-Dawley (SD) (male, 300-350 g)[5]
-
Dosage:100 μM
-
Administration:retrograde coronary perfusion
-
Result:Nimodipine (1 μM) completely blocked the positive inotropic effect of LZDO (100 μM) on LVDP, with normalized values changing from 100% (control) to 98%.\nRuthenium red (5 μM) completely blocked the positive inotropic effect of LZDO (100 μM) on LVDP, with normalized values changing from 100% (control) to 97%.\nThapsigargin (2 μM), an irreversible SR Ca2+ ATPase inhibitor, completely blocked the positive inotropic effect of LZDO (100 μM) on LVDP, with normalized values changing from 100% (control) to 95%.\nNone of the tested antagonists or inhibitors (propranolol 1 μM, IBMX 5 μM, ouabain 1 μM, prazosin 1 μM, SCH23390 1 μM, KB-R7943 1 μM) blocked the enhancing effect of LZDO (100 μM) on LVDP in isolated rat hearts.
-
Animal Model:Sprague Dawley (male, 300-350 g)[6]
-
Dosage:20 mg/kg
-
Administration:i.v.; single dose
-
Result:Decreased end-systolic volume from 82 μL to 65 μL.
Increased end-systolic pressure from 115 mm Hg to 141 mm Hg.
Increased stroke volume from 116 μL to 136 μL.
Increased ejection fraction from 58.6% to 67.6%.
Increased cardiac output from 27066 μL/min to 31312 μL/min.
Increased peak rate of rise of left ventricular pressure (+dP/dtmax) from 7207 mm Hg/s to 10022 mm Hg/s (29.2% increase).
Increased stroke work from 10395 mm Hg/μL to 14988 mm Hg/μL.
Increased slope of end-systolic pressure-volume relationship (ESPVR) from 0.96 to 1.24 (29.2% increase).
Caused no significant changes in heart rate, end-diastolic volume, end-diastolic pressure, or slope of end-diastolic pressure-volume relationship.
Chemical Information
-
CAS No. 909708-65-2
-
분자량 168.20
-
화학식 C8H12N2O2
-
SMILES
OCC1=NC(=C(N=C1C)CO)C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
ECM-Embedded Organoid (Matrigel/Dome) Culture
ECM-embedded organoid dome culture embeds epithelial stem cells, crypts, organoid fragments, or tumor-derived epithelial cells in a basement-membrane-like hydrogel such as Matrigel, allowing 3D growth, self-organization, lumen formation, budding or cystic morphogenesis, and lineage maintenance under defined niche-factor-containing medium. The primary readouts are organoid establishment efficiency, growth, morphology, passaging capacity, lineage-marker expression, and, when fluorescently labeled lines are used, microscopy- or flow-cytometry-based quantification of population behavior in 3D culture.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Matrigel Transwell/Boyden Chamber Invasion Assay
Matrigel Transwell/Boyden chamber invasion assay measures the ability of cells to degrade or traverse an extracellular matrix-coated porous membrane and move from an upper chamber toward a chemoattractant in a lower chamber. Invasion is distinguished from migration by coating the membrane with Matrigel or basement membrane matrix; uncoated inserts measure migration, while coated inserts require cells to cross an ECM barrier before reaching the underside of the membrane.
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Matrigel/ECM Transwell Invasion Assay
The Matrigel/ECM Transwell invasion assay measures the ability of cells to move toward a chemoattractant while crossing an extracellular-matrix barrier placed on a porous membrane; therefore, the readout reflects both chemotactic motility and matrix invasion rather than migration alone. Matrigel is a basement-membrane-rich matrix derived from Engelbreth-Holm-Swarm mouse sarcoma and has been used as a reconstituted basement membrane barrier in chemoinvasion assays. The assay readout is generated by quantifying cells that reach the underside of the insert membrane or lower compartment after incubation, commonly by staining and counting invaded cells or by fluorescence-based quantification.
순도&문서
References
[2]. Wu X, et al. Liguzinediol protects against cardiac fibrosis in rats in vivo and in vitro. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016 May;80:260-267. [Content Brief]
[3]. Chen Q, et al. The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism. Chinese medicine. 2020;15:63. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)